Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx-TO-OTC SWITCHES: ROLE OF FOREIGN DATA IN NDA REVIEWS

This article was originally published in The Tan Sheet

Executive Summary

Rx-TO-OTC SWITCHES: ROLE OF FOREIGN DATA IN NDA REVIEWS is one of several issues the OTC drug industry is looking to FDA to clarify, Nonprescription Drug Manufacturers Association Senior VP- Science & Technology William Soller, PhD, said at NDMA's annual marketing seminar in New York City on Jan. 12. Soller suggested that it "would be helpful in today's [regulatory] environment in relation to switch decisions" to have a "clearer understanding" of how foreign data will "be utilized by FDA to evaluate switch safety and effectiveness."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082363

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel